Olemedia Rapport Therapeutics ( NASDAQ: RAPP ) has begun trading on the NASDAQ, with an opening price of $18, above the $17 per share IPO price. The company, which is focused on treatments for central nervous system disorders, is backed by the venture capital arm of Johnson & Johnson ( JNJ ). At noon ET, shares were up ~10% .
More on Rapport Therapeutics, Inc. Rapport Therapeutics Seeks IPO For CNS Treatment Programs J&J-backed Rapport Therapeutics prices IPO at $17 per share J&J-backed Rapport Therapeutics sets terms for $136M IPO Financial information for Rapport Therapeutics, Inc..